NCT00898690

Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer

Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: DNA analysis of tumor tissue may help doctors predict how patients who receive paclitaxel will respond to treatment. PURPOSE: This laboratory study is evaluating gene expression in predicting response to paclitaxel in patients with breast cancer.

Detailed description

OBJECTIVES: * Determine whether loss of function of the FEZ1/LZTS1 gene is a predictor of response in patients with breast cancer treated with paclitaxel. OUTLINE: This is a single-blind study. Tumor tissue is analyzed for FEZ1/LZTS1 gene expression by immunohistochemistry using an antibody for the gene. Tumor expression of the gene is characterized by immunohistochemistry and scored by intensity of staining, percent of cell staining, and staining index. Tumor tissue is also analyzed for FEZ1/LZTS1 gene disruption by reverse transcriptase-polymerase chain reaction and direct sequencing. PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
GENETIC	cytogenetic analysis
GENETIC	gene expression analysis
GENETIC	microarray analysis
GENETIC	mutation analysis
GENETIC	reverse transcriptase-polymerase chain reaction
OTHER	immunohistochemistry staining method

Timeline

• Start date: 2003-03-01
• First posted: 2009-05-12
• Last updated: 2013-12-18